| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Ruan,Da-Tong | Chairman | 2.26% | |
| Zhang,Zhi-Rong | Director | 14.15% | EirGenix, Inc. |
| Huang,Xiu-Miao | Director | 7.66% | CHROMA ATE INC. |
| Huang,Li-Xin | Director | 8.01% | Taishan Buffalo No. 2 Biotech Venture Capital Limited Partnership |
| Huang,Qian-Yue | Director | 2.68% | DEVELOPMENT CENTER FOR BIOTECHNOLOGY |
| Liu,Yong-Sheng | Independent Director | 0.00% | |
| Li,Xin-Yu | Independent Director | 0.00% | |
| Lin,Heng-Zhi | Independent Director | 0.00% | |
| Wang,Bai-Sen | Independent Director | 0.00% |
Change Company Name to TFBS BIOSCIENCE, INC.
2024/05/27
Change Company Name to QIHONG BIOTECHNOLOGY CO., LTD. (FORMER NAME: QIHONG BIOTECHNOLOGY CO., LTD.)
2023/07/26
Change Capital to 600,000,000
2022/09/07
Change Capital to 300,000,000
2018/09/25
Change Company Name to TFBS BIOSCIENCE, INC.
2016/08/19
Change Person in Charge to Ruan,Da-Tong
2016/08/19
Change Company Name to None
2016/05/10
Change Person in Charge to
2016/05/10
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 91,599 | 231,916 | 252,723 |
| Operating cost | 71,770 | 154,087 | 148,674 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 19,829 | 77,829 | 104,049 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 19,829 | 77,829 | 104,049 |
| Operating expenses | 43,008 | 83,281 | 77,078 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -23,179 | -5,452 | 26,971 |
| Non-operating income and expenses | 4,241 | 10,226 | 3,739 |
| Net profit (loss) before tax | -18,938 | 4,774 | 30,710 |
| Income tax expense (benefits) | 172 | -135 | 3,017 |
| Net profit (loss) of ongoing business for the current period | -19,110 | 4,909 | 27,693 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -19,110 | 4,909 | 27,693 |
| Other comprehensive profit (loss), net | -2,750 | 12 | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -21,860 | 4,921 | 27,693 |
| Net profit (loss) attributable to owners of parent company | -19,110 | 4,909 | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -21,860 | 4,921 | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | 1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 17,475 | 36,526 | - |
| Net cash inflows (outflows) from investing activities | -207,196 | -57,631 | - |
| Net cash inflow (outflow) from financing activities | -12,356 | -25,994 | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | -3,200 | 7 | - |
| Increase (decrease) in cash and cash equivalents in the current period | -205,277 | -47,092 | - |
| Beginning balance of cash and cash equivalents | 929,345 | 976,437 | - |
| Ending balance of cash and cash equivalents | 724,068 | 929,345 | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 871,544 | 1,072,849 | 1,113,195 |
| Non-current asset | 549,280 | 375,193 | 250,207 |
| Total asset | 1,420,824 | 1,448,042 | 1,363,402 |
| Current liability | 88,088 | 84,879 | 103,811 |
| Non-current liability | 87,393 | 102,557 | 22,373 |
| Total liability | 175,481 | 187,436 | 126,184 |
| share capital | 349,217 | 347,952 | 331,146 |
| Equity - secruity token | - | - | - |
| capital reserve | 895,539 | 888,467 | 870,077 |
| retained earning | 3,325 | 24,175 | 35,995 |
| Other equity | -2,738 | 12 | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,245,343 | 1,260,606 | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,245,343 | 1,260,606 | 1,237,218 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 35 | 36 | 37 |
